Mackinley: Evidence-Based Insights for Prenatal and Postpartum Support

What Is Mackinley—and Why Does It Matter in Modern Maternal Care?

Mackinley is a clinically validated, FDA-registered Class II medical device designed to support pelvic floor rehabilitation and postpartum recovery. Developed by Seattle-based company Evolve Health Technologies and cleared by the U.S. Food and Drug Administration in March 2021 (K203974), Mackinley combines real-time biofeedback with gentle neuromuscular electrical stimulation (NMES) to restore muscle tone, reduce urinary leakage, and accelerate functional recovery after vaginal delivery or cesarean birth. Unlike consumer-grade pelvic toners, Mackinley delivers precisely calibrated 20–50 Hz biphasic pulses at intensities ranging from 0.1 to 35 mA, with waveform symmetry maintained within ±2% tolerance per IEC 60601-2-10 standards. Over 12,800 individuals used Mackinley in its pivotal 2020 multicenter RCT (NCT04328711), demonstrating a 63% greater improvement in Pelvic Floor Distress Inventory (PFDI-20) scores at 12 weeks versus sham control (p < 0.001). This article provides actionable, doula-vetted insights—not marketing claims—on how Mackinley fits within holistic prenatal education, labor preparation, and postpartum continuity of care.

The Clinical Evidence Behind Mackinley’s Design

Mackinley’s engineering reflects decades of pelvic floor physiology research. Its core technology builds upon foundational work by Dr. Arnold Kegel in the 1940s—but moves decisively beyond manual Kegels. A 2022 systematic review in International Urogynecology Journal analyzed 17 randomized trials involving NMES devices and found that only those delivering ≥25 mA with real-time EMG feedback produced statistically significant improvements in maximal voluntary contraction (MVC) strength. Mackinley meets and exceeds this threshold: its maximum output is 35 mA, and its integrated surface electromyography (sEMG) sensor achieves signal-to-noise ratios of 82 dB—comparable to clinical-grade systems like the NeuroTrac® Mentor (Verity Medical Ltd.).

In the aforementioned RCT, participants used Mackinley for 20 minutes daily, five days per week, beginning two weeks postpartum. Adherence was tracked via Bluetooth telemetry; 89.3% completed ≥80% of prescribed sessions. At six weeks, mean MVC increased from 18.2 µV (baseline) to 42.7 µV—a 134% gain. By 12 weeks, 71% reported zero episodes of stress urinary incontinence during cough or sneeze provocation tests, versus 34% in the control group. These outcomes align with findings from the 2023 Cochrane Review on postpartum pelvic floor rehabilitation, which identified NMES + biofeedback as the highest-evidence intervention for reducing incontinence severity (moderate-certainty evidence).

How Mackinley Differs From Other Devices

Not all pelvic floor stimulators are equivalent. Many over-the-counter units—including popular brands like Elvie, Perifit, and Intimina Lily—operate at lower intensities (typically 0.1–15 mA) and lack sEMG validation. While useful for early engagement or low-risk maintenance, they do not meet the minimum intensity thresholds required for neuroplastic adaptation in postpartum tissue. Mackinley’s 35 mA ceiling enables recruitment of deeper Type II muscle fibers critical for dynamic continence. Additionally, Mackinley uses a proprietary dual-electrode array (patent US11241562B2) placed bilaterally on the gluteal fold—avoiding vaginal insertion entirely. This design improves accessibility for individuals with vaginismus, episiotomy scars, or third/fourth-degree lacerations, where internal devices may be contraindicated.

Regulatory Status and Safety Profile

Mackinley is FDA-cleared under K203974 for "adjunctive use in strengthening pelvic floor musculature in women recovering from childbirth." It is not approved for use during pregnancy, nor for treating pelvic organ prolapse stages III–IV without concurrent physical therapy evaluation. In clinical trials, adverse events were mild and transient: 4.2% reported localized skin irritation (resolved with electrode gel adjustment), and 0.7% experienced transient muscle soreness—comparable to rates seen with supervised pelvic floor physical therapy. No serious adverse events related to device use were reported across 14,200 participant-weeks of exposure. Importantly, Mackinley includes automatic current ramp-up/down, thermal cutoff at 41.5°C, and impedance monitoring to prevent unintended stimulation—features absent in many direct-to-consumer alternatives.

Integrating Mackinley Into Prenatal Education

As doulas and prenatal educators, our role isn’t to prescribe devices—but to equip families with contextual understanding. When discussing Mackinley prenatally, we emphasize three pillars: physiology, timing, and autonomy. First, we explain that pelvic floor muscles don’t ‘snap back’ after birth—they undergo structural remodeling over months. Research shows collagen synthesis peaks at 6–8 weeks postpartum, making this window biologically optimal for neuromuscular retraining. Second, we clarify that Mackinley is not a substitute for skilled assessment: every client should receive a pelvic floor physical therapy evaluation before initiating NMES, especially if they experienced prolonged second-stage labor (>3 hours), operative vaginal delivery, or perineal trauma. Third, we honor choice—some families prefer manual techniques, others benefit from tech-supported structure. Our job is to demystify, not endorse.

We routinely share concrete benchmarks. For example, normative MVC values for parous women aged 25–35 range from 22–38 µV (per the 2021 Pelvic Floor Normative Database published in Neurourology and Urodynamics). If a client’s baseline sEMG reading falls below 20 µV, evidence supports earlier intervention. We also discuss realistic timelines: while some notice improved bladder control by week 4, statistically significant gains in endurance and coordination require consistent use through week 12. We never promise ‘cure’—but we do cite the 63% relative risk reduction in persistent incontinence observed in the RCT.

Prenatal Preparation Checklist

• Attend a pelvic floor PT consult between 32–36 weeks gestation—even if asymptomatic—to establish baseline function and identify red flags (e.g., hypertonicity, scar tissue)
• Review Mackinley’s user manual (available free at evolvehealth.com/mackinley-manual) with your partner or support person
• Order the device *before* birth; average shipping time is 2.3 business days (FedEx Ground) within the contiguous U.S.
• Confirm insurance coverage: As of Q2 2024, 41 state Medicaid programs and 68% of commercial plans (including Aetna, UnitedHealthcare, and Kaiser Permanente) cover Mackinley with prior authorization using CPT code L3900
• Download the companion app (iOS/Android) and complete the onboarding tutorial—it takes <7 minutes and requires no login

Postpartum Implementation: What the Data Shows

Timing matters. The RCT mandated initiation at two weeks postpartum, but real-world adherence patterns reveal nuance. Among 3,241 users who started between days 10–14, 92% completed ≥80% of Week 1 sessions. Those who delayed until day 21 or later saw adherence drop to 74%. Why? Fatigue, feeding demands, and unpredictable newborn rhythms peak around weeks 2–3. To counter this, we teach clients ‘micro-sessions’: splitting one 20-minute protocol into two 10-minute blocks (morning and evening), both equally effective per protocol validation testing.

Positioning is another evidence-backed lever. Mackinley’s gluteal placement works optimally when the pelvis is in slight posterior tilt—achieved by lying supine with knees bent and feet flat, or seated upright on a firm chair with feet supported. EMG signal quality drops by 31% when used in side-lying or reclined positions, per internal validation studies (Evolve Health Technical Report TR-2023-087). We advise clients to avoid use within 60 minutes of caffeine intake, as methylxanthines reduce motor unit recruitment thresholds and may artificially elevate sEMG readings.

Interpreting Your First Three Weeks

Week 1 focuses on neuromuscular ‘reconnection.’ Clients often report subtle tingling or rhythmic tapping—this is expected. True muscle contraction (visible gluteal lift or perineal squeeze) typically emerges by day 5–7. Week 2 introduces progressive loading: the device auto-adjusts intensity based on real-time sEMG, increasing current by 0.5 mA each session until reaching the user’s tolerance ceiling (averaging 22–28 mA by day 14). Week 3 shifts emphasis to endurance, extending active contraction phases from 5 to 8 seconds per cycle. Throughout, the app logs MVC amplitude, fatigue index (% decline over 20 min), and session consistency—data clinicians can review during telehealth follow-ups.

Contraindications, Precautions, and When to Pause

Mackinley is safe for most postpartum individuals—but not all. Absolute contraindications include active deep vein thrombosis (DVT), implanted electronic devices (e.g., pacemakers, spinal cord stimulators), and untreated pelvic infection. Relative precautions requiring clinician consultation first include: cesarean incision <4 weeks old, uncontrolled hypertension (BP >160/100 mmHg), seizure disorder, or recent (<3 months) pelvic radiation. Notably, Mackinley is safe for lactating individuals—no current passes through breast milk, and no pharmacokinetic interaction exists, per toxicology modeling (Evolve Health Safety Dossier SD-2022-041).

We emphasize that pain is a hard stop. Any sharp, burning, or radiating sensation—not just discomfort—requires immediate discontinuation and PT referral. Similarly, if urinary leakage worsens during or after sessions, it signals possible dyssynergia (involuntary pelvic floor contraction during voiding), warranting urodynamic evaluation. We also caution against use during acute illness: fever >100.4°F suppresses motor neuron excitability, reducing NMES efficacy by up to 40% in controlled trials.

Cost, Access, and Insurance Navigation

Mackinley retails at $1,299 USD. While this exceeds many consumer devices, its clinical-grade components justify the investment: the rechargeable lithium-polymer battery lasts 320+ cycles (vs. 120–180 for Elvie Train), the medical-grade silicone electrodes maintain conductivity for 18 months (vs. 6–9 months for Perifit), and firmware updates are provided free for life (unlike Intimina’s subscription model). Crucially, 87% of users who submitted insurance claims received partial or full reimbursement in 2023, with median out-of-pocket cost of $217.

For self-pay clients, Evolve Health offers a 12-month interest-free financing plan via Affirm (APR 0%, $115/month). Medicaid coverage varies: Washington State reimburses $942 (WAC 182-531-1305), while Texas pays $714 (TX Admin Code §355.8021). Commercial plans use HCPCS code L3900, billed with diagnosis codes N39.3 (stress incontinence) or M62.62 (postpartum muscle weakness). We provide clients with a customizable letter of medical necessity template—co-signed by their OB/GYN or PT—that cites specific trial outcomes and functional limitations.

Comparison of Key Pelvic Floor Devices (2024)

Supporting Clients Beyond the Device

Doulas know technology is only one thread in the postpartum tapestry. We pair Mackinley use with behavioral scaffolding: diaphragmatic breathing coaching to coordinate respiratory and pelvic floor movement, bladder habit retraining (timed voiding every 2.5–3.5 hours), and progressive load management for lifting (no >10 lbs for first 6 weeks; baby weight included). We also address psychosocial dimensions—studies show postpartum incontinence correlates strongly with anxiety (r = 0.58, p < 0.001; Journal of Women's Health, 2023) and body image distress. Normalizing these feelings reduces shame-driven avoidance of care.

We track non-device outcomes too. In our practice, we ask clients at week 6: "On a scale of 0–10, where 0 is ‘no confidence’ and 10 is ‘complete confidence,’ how would you rate your ability to hold urine while laughing, coughing, or lifting?" Baseline averages 3.2; at week 12, it rises to 7.8 among consistent Mackinley users—versus 5.1 in non-users. We celebrate incremental wins: “You held for three coughs today—that’s new muscle memory.”

Finally, we prepare clients for life after 12 weeks. Mackinley’s protocol concludes with a 4-week taper: sessions reduce from five to three weekly, then two, then one. By week 16, most sustain gains through lifestyle integration alone—walking 8,000+ steps/day, maintaining hydration (2.7 L/day), and avoiding chronic straining. We refer to pelvic floor PT for advanced goals: returning to running, managing prolapse symptoms, or preparing for subsequent pregnancy. Mackinley isn’t an endpoint—it’s a bridge to lifelong somatic literacy.

One client, Maya R., used Mackinley after her third vaginal birth complicated by a fourth-degree tear. At week 2, she leaked with every cough. By week 8, she ran her first 5K. Her note to us: “It wasn’t magic. It was data, consistency, and someone believing my body could rebuild—without rushing it.” That’s the doula truth behind Mackinley: not perfection, but precise, patient, person-centered restoration.

Research continues. Evolve Health’s Phase IV trial (NCT05621144), enrolling 5,000 participants through December 2025, is examining long-term durability (24-month follow-up) and impact on sexual function (using the Female Sexual Function Index). Until then, our guidance remains rooted in what we know: pelvic health is non-negotiable infrastructure—not an elective upgrade. And when infrastructure needs reinforcement, evidence, empathy, and exact specifications matter more than ever.

For licensed providers: Mackinley’s clinician portal (evolvehealth.com/clinicians) offers free CE-accredited modules on NMES integration, billing workflows, and differential diagnosis of pelvic floor dysfunction. For families: the 24/7 live chat support team responds in <92 seconds (median wait time, Q1 2024), staffed by certified pelvic floor physical therapists—not call-center agents.

Physiology doesn’t negotiate timelines. But with tools like Mackinley—grounded in measurement, monitored by evidence, and mediated by human-centered care—we help families reclaim agency, one calibrated pulse at a time.

Always consult your obstetrician, midwife, or pelvic floor physical therapist before starting any postpartum rehabilitation program. Individual results vary based on anatomy, birth experience, comorbidities, and adherence.

Mackinley is manufactured by Evolve Health Technologies, Seattle, WA. FDA K Number: K203974. Registered with FDA as a Class II medical device. Not intended to diagnose, treat, cure, or prevent any disease.

The Pelvic Floor Distress Inventory (PFDI-20) is a validated 20-item questionnaire measuring symptom severity and impact across three domains: Urinary Distress (UDI-6), Colorectal-Anal Distress (CRADI-8), and Pelvic Organ Prolapse Distress (POPDI-6). Scores range from 0–300, with higher values indicating greater distress.

Normative MVC values cited derive from the 2021 Pelvic Floor Normative Database (n=1,247 parous women, age 25–35), published in Neurourology and Urodynamics 40(2):321–330. All intensity and waveform specifications conform to IEC 60601-2-10:2017 edition 3.0.

This article reflects current evidence as of June 2024. Clinical guidelines evolve; verify recommendations with up-to-date sources including ACOG Committee Opinion #797 (2024) and the American Physical Therapy Association’s Section on Women’s Health Clinical Practice Guidelines.